ARM I: Patients receive obinutuzumab intravenously (IV) on day 1 and PI3K-delta inhibitor TGR-1202 orally (PO) daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.